Neuraxial anesthesia encompasses the introduction of local anesthetic into the subarachnoid space (spinal anesthesia) or the epidural space (epidural anesthesia), and represents the most powerful and comprehensive application of local anesthetic pharmacology in clinical medicine. A single spinal injection of 2–3 mL of local anesthetic can produce complete surgical anesthesia of the lower half of the body within minutes; an epidural catheter can sustain this effect for hours to days, with the flexibility to titrate depth of block to changing clinical needs. The pharmacology of neuraxial local anesthetics differs substantially from peripheral nerve block pharmacology: the anatomic barriers, distribution kinetics, and the proximity of drug to the spinal cord and brainstem create a distinct pharmacokinetic environment that determines block onset, level, density, and duration in ways that cannot be predicted from the physicochemical properties of the drug alone.1 This module provides the in-depth treatment of neuraxial pharmacology, obstetric applications, complications, and continuous catheter techniques that the breadth of CNS-LA-03 precluded. It assumes familiarity with the basic spinal and epidural pharmacology introduced there and builds the clinical depth required for T3 and T4 question scenarios.
The subarachnoid space presents a pharmacokinetic environment fundamentally different from any other drug delivery site in clinical use. Local anesthetic injected intrathecally is deposited directly into cerebrospinal fluid (CSF), bypassing all the tissue barriers that ordinarily slow drug penetration to neural tissue. The drug is in immediate contact with the nerve roots of the cauda equina and, depending on spread, with the spinal cord itself. There is no perineurial barrier, no fascial plane, and no tissue buffer; effective drug concentrations at the target tissue are achieved within seconds of injection. The flip side is that the subarachnoid space provides no pharmacokinetic buffer against overdose: a dose that produces a T4 sensory level in one patient may produce a T1 level and respiratory compromise in another, depending on baricity, position, CSF volume, and individual anatomy.1
Drug removal from the subarachnoid space occurs through two primary mechanisms: vascular uptake by the spinal cord vasculature and pial vessels, and bulk CSF flow carrying drug toward the brain. Lipid-soluble agents (bupivacaine, tetracaine) are removed primarily by vascular uptake into the spinal cord and adjacent tissues, producing a relatively localized block that persists until tissue concentrations fall. Less lipid-soluble agents (chloroprocaine, mepivacaine) are removed faster by both mechanisms, producing shorter and somewhat less predictable block spread. Intrathecal opioids follow similar principles: highly lipid-soluble opioids (fentanyl, sufentanil) are rapidly taken up by the spinal cord and produce segmental analgesia with minimal rostral spread; poorly lipid-soluble morphine remains in CSF longer and spreads rostrally over hours, providing extended analgesia but with delayed respiratory depression risk up to 18–24 hours post-injection.2
The level of spinal block achieved is primarily determined by the total mass of drug injected (milligrams, not volume or concentration), the baricity of the solution relative to CSF, patient position during and immediately after injection, and the anatomy of the subarachnoid space. Baricity is the ratio of the density of the injectate to the density of CSF at 37°C; CSF has a density of approximately 1.003–1.009 g/mL. Hyperbaric solutions (bupivacaine in 8% dextrose, density approximately 1.023 g/mL) are heavier than CSF and sink to the most dependent portion of the subarachnoid space; the clinician directs cephalad spread by placing the patient in Trendelenburg position, or sacral concentration by keeping the patient sitting. Isobaric solutions (plain bupivacaine 0.5%) remain roughly at the level of injection with limited positional influence, producing a block whose level is more predictable from the dose and injection site but less manipulable by positioning.1
Patient factors that increase the cephalad spread of a given intrathecal dose include advanced age (reduced CSF volume from ligamentous hypertrophy and vertebral osteophytes narrowing the space), pregnancy at term (engorged epidural veins compressing the subarachnoid space and reducing CSF volume), obesity (increased intra-abdominal pressure transmitted to the epidural space), and short stature (smaller absolute subarachnoid volume for the same lumbar volume). These factors explain why the elderly parturient requires a substantially smaller intrathecal bupivacaine dose for cesarean delivery than a young male undergoing inguinal herniorrhaphy, despite the target block level being similar. The practical approach is to use weight-based dose adjustments for body habitus extremes and to recognize that the relationship between dose and block level is not linear; small dose reductions produce disproportionately lower block levels in patients at the extremes of the predictive variables.1
Hyperbaric bupivacaine 0.5% remains the dominant agent for spinal anesthesia globally, offering dense and reliable surgical block of 90–150 minutes at standard doses of 10–15 mg for lower abdominal, pelvic, and lower extremity surgery. For perineal and anorectal procedures in the sitting position (saddle block), 5–7.5 mg concentrated into the lumbosacral segments produces surgical anesthesia without significant motor block of the lower extremities.1 The addition of intrathecal fentanyl 10–25 μg or sufentanil 2.5–5 μg improves intraoperative analgesia, reduces local anesthetic dose requirements (allowing dose reduction of 10–20% for equivalent block quality), and provides early postoperative analgesia through spinal opioid receptor activation; these benefits come with a modest increase in nausea and pruritus. Intrathecal morphine 100–200 μg provides 12–24 hours of postoperative analgesia but requires extended monitoring for delayed respiratory depression, typically 18–24 hours of nursing observation in facilities following standard protocols.2
Preservative-free chloroprocaine 1–2% (30–45 mg) has established itself as the preferred agent for ambulatory spinal anesthesia in procedures expected to last 30–60 minutes, offering rapid onset (5–10 minutes to dense block), complete resolution within 60–90 minutes, and essentially zero risk of transient neurologic symptoms at clinical doses, a significant advantage over hyperbaric lidocaine 5%, which carries a TNS incidence of 4–40% in published series. The very short duration is both the strength and the limitation of chloroprocaine spinal anesthesia: it is unsuitable for procedures with variable or unpredictable duration, and the absence of meaningful postoperative analgesia beyond the block period requires a robust oral analgesic plan to be established before discharge.3
The epidural space is a potential space containing areolar connective tissue, fat, lymphatics, and a rich venous plexus. It is not a simple fluid-filled compartment like the subarachnoid space; injected local anesthetic must distribute through a heterogeneous tissue matrix, cross the dura mater, and reach the nerve roots within their dural sleeves (the points of least resistance) to produce neural blockade. The volume of distribution within the epidural space is substantially larger than the subarachnoid compartment, which accounts for the 5–10-fold higher doses required for equivalent block levels compared to spinal anesthesia. Epidural fat and connective tissue act as local reservoirs, absorbing drug from the injected solution and releasing it slowly, a process that contributes to the prolonged and graded action of epidural anesthetics compared to the rapid and complete block produced intrathecally.1
The spread of epidural local anesthetic is determined primarily by volume injected (larger volumes spread over more spinal segments), patient age and anatomy (elderly patients have reduced epidural fat and more predictable spread per volume; scoliosis and prior surgery produce unpredictable distribution), the injection rate (faster injection produces wider initial spread), and the catheter tip position. Concentration determines block density rather than spread: 0.0625% bupivacaine in a large volume produces sensory block without motor block; 0.5% bupivacaine in the same volume produces dense sensorimotor block. This concentration-density relationship is the pharmacologic basis for tailoring epidural solutions to specific clinical goals, a principle exploited most visibly in obstetric epidural practice, where the concentration is titrated to provide pain relief while preserving the motor function needed for pushing and ambulation.1
The epidural test dose is a critical safety step that exploits two pharmacologic markers to detect catheter misplacement before the full therapeutic dose is administered. The standard test dose consists of 3 mL of lidocaine 1.5% with epinephrine 1:200,000 (total: 45 mg lidocaine and 15 μg epinephrine). If the catheter is positioned intravascularly, the 15 μg epinephrine produces a heart rate increase of ≥20 bpm within 45–60 seconds, a response that is rapid, quantifiable, and does not require patient cooperation; it is the most reliable marker of intravascular injection in awake patients. If the catheter is in the subarachnoid space rather than the epidural space, 45 mg lidocaine produces a rapidly ascending dense motor block within 2–3 minutes, detectable as progressive lower extremity weakness well before the full epidural dose would have been administered.1
The test dose has recognized limitations that must be understood rather than dismissed. In obstetric patients receiving oxytocin infusions, uterine contractions produce transient maternal tachycardia that can obscure the epinephrine-induced heart rate increase; testing should be performed during a quiescent inter-contraction interval with baseline heart rate documented immediately before injection. In patients receiving β-adrenergic blockers, the heart rate response to 15 μg epinephrine is blunted or absent; in these patients, alternative intravascular injection markers must be sought: hypertension, palpitations, or the T-wave changes detectable on continuous ECG may be the only indicators. In patients under general anesthesia, neither the heart rate response (masked by hemodynamic variability) nor the motor block response (masked by neuromuscular blockade) is reliable, and the test dose provides less safety assurance than in awake patients.1
The choice of local anesthetic for epidural use is dictated by the clinical goal (analgesia versus surgical anesthesia), the required onset speed, the duration of effect needed, and the patient’s physiologic context. For labor analgesia, the dominant current approach uses bupivacaine 0.0625–0.1% or ropivacaine 0.1–0.2% combined with fentanyl 1–2 μg/mL, often delivered as patient-controlled epidural analgesia (PCEA) with a background infusion. This combination achieves effective labor pain relief at concentrations well below the motor block threshold for most patients, allowing ambulation and full lower extremity strength. For conversion to surgical anesthesia for cesarean delivery under an existing labor epidural, 3% chloroprocaine 15–20 mL provides the fastest and most reliable onset (6–10 minutes to surgical block), exploiting the high chloroprocaine concentration to overcome its ionization disadvantage by mass action; 2% lidocaine with epinephrine 1:200,000 and bicarbonate is an acceptable alternative with onset of 10–15 minutes.1
For postoperative epidural analgesia, thoracic epidural catheters (placed at the dermatomal level of the surgical incision) provide the most effective and opioid-sparing analgesia for thoracic, upper abdominal, and open cardiac procedures. The preferred infusion for thoracic epidural analgesia is bupivacaine 0.0625–0.125% with fentanyl 2–4 μg/mL or hydromorphone 5–10 μg/mL at 5–10 mL/h, titrated to maintain a sensory level appropriate to the incision while minimizing lower extremity motor block. The thoracic epidural’s sympathectomy of the cardiac accelerator fibers (T1–T4) reduces myocardial oxygen demand and may improve outcomes in patients with coronary artery disease undergoing major surgery, an additional benefit beyond analgesia that is supported by observational data and biologically plausible mechanism.5
The pregnant patient at term presents pharmacokinetic and physiologic challenges that make neuraxial anesthesia both more necessary and more technically demanding than in the non-pregnant population. Aortocaval compression by the gravid uterus is the most immediately consequential anatomic change: in the supine position, the uterus compresses both the inferior vena cava (reducing venous return and cardiac output by up to 30%) and the abdominal aorta. Engorged epidural veins secondary to this inferior vena cava (IVC) compression reduce the volume of both the subarachnoid and epidural spaces, meaning that the same intrathecal or epidural dose produces a higher and more unpredictable block level than in a non-pregnant patient. Left uterine displacement (achieved by a left tilt of 15° or a wedge under the right hip) is mandatory throughout any procedure under neuraxial anesthesia in a term parturient, as aortocaval compression in the supine position can produce catastrophic maternal hypotension that compromises placental perfusion and fetal oxygenation.1
Sympathetic block from spinal or epidural anesthesia produces vasodilation and hypotension that is more severe and more rapid in onset in pregnant patients than in non-pregnant individuals, for two reasons: baseline vasodilation of pregnancy (progesterone-mediated) means there is less sympathetic vasomotor reserve to lose, and the mechanical compression of the aorta by the uterus means that hypotension preferentially reduces uteroplacental blood flow at arterial pressure levels that may be well-tolerated hemodynamically in the mother. Phenylephrine has become the vasopressor of choice for prevention and treatment of spinal anesthesia-induced hypotension in obstetric patients, based on randomized trial evidence demonstrating superior maintenance of uteroplacental blood flow compared to ephedrine, despite producing lower maternal heart rates; an infusion of phenylephrine 25–50 μg/min titrated to systolic pressure is the current standard approach for elective cesarean delivery under spinal anesthesia.1
The contemporary approach to labor epidural analgesia has evolved from continuous epidural infusion to programmed intermittent epidural bolus (PIEB) delivery combined with patient-controlled epidural analgesia (PCEA) demand dosing. PIEB delivers scheduled boluses (e.g., 8–10 mL of 0.0625% bupivacaine with fentanyl 2 μg/mL every 30–45 minutes) rather than a continuous infusion at the same hourly rate. The intermittent bolus produces more uniform spread of solution within the epidural space, reaching more lateral epidural recesses and filling the space more completely than a slow continuous flow, resulting in better dermatomal coverage, lower local anesthetic consumption, and superior analgesia scores compared to continuous infusion at equivalent total doses.1 Breakthrough pain despite an apparently functioning epidural catheter most commonly reflects inadequate block of the posterior sacral roots (often incompletely reached in the sitting epidural position), unilateral block from catheter tip migration to a lateral position, or an excessively high sensory level producing paradoxical breakthrough from rectal and pelvic pressure sensations that are not local anesthetic-suppressible at the concentration being used.
Late labor provides a specific pharmacologic challenge: as delivery approaches and the fetal presenting part descends, intense sacral root pressure creates perineal pain that often requires a concentration increase (from 0.0625% to 0.125% bupivacaine) or patient repositioning to seated for 15–20 minutes to direct hyperbaric solution toward the sacral nerve roots. The distinction between a poorly functioning epidural catheter and a catheter that is functioning correctly but inadequately dosed for the stage of labor is a clinical skill that requires understanding of both the anatomy of sacral nerve root coverage and the concentration-density relationship of epidural local anesthetics.
Single-shot spinal anesthesia is the technique of choice for elective and most urgent cesarean deliveries, offering rapid, reliable, dense surgical anesthesia with minimal fetal drug exposure. The standard regimen is hyperbaric bupivacaine 0.5% 10–12.5 mg with intrathecal fentanyl 15–25 μg and intrathecal morphine 100–150 μg, targeting a T4 sensory level bilaterally (assessed to pinprick or cold sensation at the nipple line). The addition of intrathecal morphine provides 18–24 hours of postoperative analgesia and dramatically reduces parenteral opioid requirements in the first postoperative day, enabling earlier breastfeeding and neonatal bonding; its risk of delayed respiratory depression requires 18–24 hour nursing observation, which is standard on postpartum units where intrathecal morphine is routine.2 Failed spinal requiring conversion to general anesthesia in obstetrics carries significantly higher maternal morbidity (airway management difficulty in the pregnant airway, aspiration risk, fetal exposure to general anesthetic agents) and should be anticipated and mitigated by appropriate dose selection, immediate recognition of inadequate block, and rapid decision-making about supplementation versus conversion.
The combined spinal-epidural (CSE) technique places a spinal needle through an epidural needle already seated in the epidural space (the needle-through-needle approach), allowing a subarachnoid injection of local anesthetic for rapid block onset followed by epidural catheter placement for duration extension and dose titration. The technique provides the speed and density of spinal anesthesia with the flexibility and duration extension of epidural catheterization, and is particularly valued in two clinical contexts: labor analgesia initiation and high-risk surgical patients requiring precise neuraxial management.1
For labor analgesia, the CSE technique using intrathecal sufentanil 2.5–5 μg or fentanyl 15–25 μg (with or without a very small dose of intrathecal bupivacaine 1–2.5 mg) produces rapid, dense analgesia within 5–10 minutes that is particularly effective for severe early labor pain or for patients presenting in advanced labor who require rapid pain control. The intrathecal opioid alone at these doses provides analgesia without motor block, enabling the patient to remain ambulatory while the epidural catheter is secured and tested. As the spinal opioid effect wanes (30–90 minutes for sufentanil), the epidural infusion is initiated to maintain analgesia through delivery. A practical concern with CSE is that the epidural catheter cannot be reliably tested for intrathecal placement immediately after the subarachnoid injection, since the sensory and motor block from the spinal component will obscure the motor block test dose response; catheter testing is deferred until the spinal block has partially resolved, typically 30–45 minutes after intrathecal injection.1
For surgical anesthesia, particularly for complex lower extremity or pelvic procedures where the required block duration is uncertain, the CSE technique allows a lower initial intrathecal dose to be supplemented epidurally as needed. A spinal dose of 7.5–10 mg bupivacaine (below the dose required for reliable solo spinal anesthesia) combined with epidural supplementation titrated to block level allows the clinician to achieve the target block level with precision while reducing the hemodynamic impact of the inevitable sympathectomy, a significant advantage in high-risk cardiac patients where the sympathectomy from a full spinal dose can produce rapid profound hypotension.
High spinal block refers to unintended cephalad spread of spinal anesthesia to thoracic or cervical levels, producing sympathetic blockade of the cardiac accelerators (T1–T4), intercostal muscle paralysis (T1–T12), and at the most extreme, phrenic nerve blockade (C3–C5) resulting in diaphragmatic paralysis and respiratory arrest. Total spinal anesthesia (inadvertent subarachnoid injection of an epidural dose of local anesthetic, or extreme cephalad spread of an intrathecal dose) produces unconsciousness, apnea, and cardiovascular collapse from combined sympathectomy-induced vasodilation and reduced cardiac preload.1 The treatment of high or total spinal is supportive: supplemental oxygen or endotracheal intubation for respiratory compromise, aggressive IV fluid resuscitation (500–1000 mL crystalloid rapidly), vasopressor support with phenylephrine or ephedrine (ephedrine preferred if accompanied by bradycardia, as it provides both α- and β-adrenergic support), and atropine for vagally-mediated bradycardia from unopposed parasympathetic tone on the denervated heart. The block will resolve spontaneously as drug is removed from the cerebrospinal fluid (CSF); resuscitation in the interim may need to be sustained for 30–90 minutes.
Post-dural puncture headache (PDPH) results from loss of CSF through the dural puncture site, producing a reduction in CSF pressure that allows caudal displacement of intracranial structures and traction on pain-sensitive meningeal structures when the patient is upright. The headache is characteristically postural: absent or mild when supine, and severe (often disabling) when the patient sits or stands. Associated symptoms include neck stiffness, photophobia, and tinnitus from the concurrent intracranial hypotension. Risk factors for PDPH include needle gauge (smaller needle, lower risk), needle bevel orientation (pencil-point needles such as Whitacre and Sprotte produce substantially less PDPH than cutting Quincke needles at the same gauge), patient age (younger patients have higher CSF pressure and a more vigorous cough reflex that enlarges the dural hole), and female sex.3
Conservative management (bed rest, aggressive oral hydration, caffeine) is appropriate for mild to moderate PDPH but is incompletely effective and does not address the underlying dural leak. The epidural blood patch (EBP) is the definitive treatment for disabling PDPH: 15–20 mL of autologous blood is injected into the epidural space at or below the level of the dural puncture, where it clots and seals the dural hole, restoring normal CSF pressure within minutes. The EBP produces immediate or near-immediate headache relief in approximately 85–90% of patients with a single procedure; a second patch is effective in the majority of the remainder. The procedure carries a small risk of transient nerve root irritation from the blood bolus and a theoretical (clinically rare) risk of epidural infection.3
Epidural hematoma is the most feared neuraxial complication and constitutes a neurosurgical emergency: accumulation of blood in the epidural space compresses the spinal cord or cauda equina, producing progressive motor weakness, sensory loss, and bowel/bladder dysfunction that, if not decompressed within 8–12 hours of onset, results in permanent neurologic deficit. The incidence is estimated at 1 in 150,000 for epidural anesthesia in the general population, but is substantially higher in anticoagulated patients. Neuraxial anticoagulation guidelines (published by the American Society of Regional Anesthesia and Pain Medicine (ASRA) and regularly updated) specify minimum intervals between last anticoagulant dose and neuraxial needle placement or catheter removal, and between catheter removal and resumption of anticoagulation; these intervals vary by anticoagulant class, dose, and patient renal function, and must be observed rigorously in every patient receiving neuraxial anesthesia.5 The clinical presentation is new or worsening neurologic deficit in a patient with a neuraxial catheter or following recent neuraxial procedure; urgent MRI of the spine is the diagnostic modality of choice, and neurosurgical decompression should not be delayed for any reason in a patient with a confirmed or strongly suspected epidural hematoma.
Epidural abscess presents similarly to hematoma but typically over a slower time course (days rather than hours), often with fever, back pain at the insertion site, and leukocytosis preceding neurologic deterioration. The organism is most commonly Staphylococcus aureus. Risk factors include immunosuppression, diabetes mellitus, prolonged catheter dwell time (beyond 4–5 days), breach of aseptic technique during insertion, and bacteremia from a distant source. Treatment is urgent neurosurgical decompression combined with pathogen-directed antibiotics; conservative antibiotic therapy alone is associated with worse neurologic outcomes than surgical decompression in the setting of neurologic deficit.
Continuous peripheral nerve block (CPNB) catheters extend the analgesic benefit of a single-injection nerve block from the 8–16 hour window of a single long-acting agent injection to 48–72 hours or more, covering the period of peak postoperative pain and significantly reducing opioid requirements during the most pain-intensive portion of recovery. The catheter is placed adjacent to the target nerve or plexus using ultrasound guidance, typically through a 17–18 gauge Tuohy needle, with a flexible polyamide catheter threaded 2–5 cm beyond the needle tip. Correct positioning is confirmed by observation of injectate spread adjacent to the target nerve under real-time ultrasound.6
The infusion solution for CPNB typically consists of ropivacaine 0.1–0.2% or bupivacaine 0.0625–0.125% delivered at 5–10 mL/h by programmable infusion pump, with an on-demand bolus option of 5 mL every 30–60 minutes for breakthrough pain. Ropivacaine is generally preferred for continuous infusions given its modestly wider cardiac safety margin and equivalent analgesic efficacy. The primary pharmacokinetic concern with extended infusions is drug accumulation: total daily bupivacaine delivery of 100–200 mg at analgesic concentrations is within safe limits for most patients, but patients with hepatic disease, reduced cardiac output, low body weight, or very long catheter dwell times require reduced infusion rates and monitoring for early CNS toxicity symptoms.6 Ambulatory CPNB, sending patients home with a portable infusion pump and catheter in place, is now standard practice for major shoulder, knee, and foot surgery in ambulatory surgical centers; patient education about LAST symptoms, fall precautions (from motor block), and catheter site care is essential for safe outpatient use.
Continuous epidural infusions for postoperative pain management are most commonly delivered as a combination of dilute local anesthetic and opioid, exploiting the synergy between epidural opioid receptor activation and local anesthetic conduction blockade to achieve analgesia at concentrations lower than either agent alone would require. Standard postoperative thoracic epidural infusions use bupivacaine 0.0625–0.125% with fentanyl 2–4 μg/mL or hydromorphone 5–10 μg/mL at 4–8 mL/h, adjusted based on dermatomal block assessment. The adequacy of analgesia is assessed by bilateral cold or pin-prick sensation testing to confirm that the catheter-tip level covers the surgical incision.5
Motor block assessment is a mandatory component of epidural catheter monitoring: unexpected or progressive lower extremity motor weakness in a patient with a postoperative epidural catheter requires systematic evaluation to distinguish pharmacologic over-blockade from catheter migration (intrathecal or intravascular) or epidural hematoma. The first intervention for unexpected motor block is to reduce or stop the infusion and reassess after 30–60 minutes; motor weakness that resolves with infusion reduction is almost certainly pharmacologic and can be managed by concentration or rate reduction. Motor weakness that persists or progresses after infusion reduction requires urgent evaluation for epidural hematoma by MRI. The catheter removal itself carries risk in anticoagulated patients: the same intervals that govern catheter insertion also govern safe removal, and removing a catheter at the wrong time relative to anticoagulant administration carries hematoma risk comparable to insertion in an anticoagulated patient.5
Enhanced recovery after surgery (ERAS) protocols are built on the principle of attenuating the surgical stress response through multimodal preemptive and perioperative interventions that together achieve faster recovery than any single intervention alone. Neuraxial anesthesia is the pharmacologic cornerstone of ERAS for major thoracic, abdominal, and orthopedic surgery, providing three complementary benefits that no systemic analgesic can fully replicate: opioid-sparing analgesia (eliminating opioid-related adverse effects that are the primary drivers of delayed recovery), sympathetic blockade of the operative field (reducing the neurohumoral stress response and attenuating the hypercoagulable and immunosuppressive consequences of surgical trauma), and preserved gut motility (critical for colorectal and other abdominal ERAS protocols).7
The evidence base for thoracic epidural analgesia in colorectal ERAS is the strongest of any regional analgesic modality: multiple randomized trials and meta-analyses demonstrate reduced rates of postoperative ileus, shorter time to first flatus and oral intake, reduced pulmonary complications, and shorter hospital length of stay compared to systemic opioid analgesia. The Cochrane review of epidural analgesia versus opioid-based analgesia for abdominal surgery consistently demonstrates superiority of epidural analgesia for gastrointestinal recovery, pain scores, and pulmonary outcomes.7 The ERAS Society guidelines for colorectal surgery recommend thoracic epidural analgesia as the preferred analgesic modality for open colonic resection, and reserve alternative techniques (spinal analgesia with intrathecal morphine, transversus abdominis plane (TAP) block, wound infiltration catheters) for laparoscopic and robotic approaches where the peritoneal incision burden is lower.
The rapid growth of laparoscopic and robotic surgery has reshaped the neuraxial anesthesia landscape over the past decade. For laparoscopic colectomy, laparoscopic prostatectomy, and robotic hysterectomy, the smaller incision burden reduces postoperative pain intensity to a level manageable with intrathecal morphine (100–200 μg providing 18–24 hours of analgesia), multimodal oral analgesia, and fascial plane blocks such as TAP or quadratus lumborum blocks, without the catheter-related risks and monitoring burden of a thoracic epidural. The balance point between epidural analgesia and these alternative strategies depends on the specific procedure, the patient’s risk factors for epidural complications, and institutional expertise.7 Understanding when to advocate for neuraxial anesthesia, and when an equally effective, lower-risk alternative exists, is the clinical application of the pharmacokinetic and pharmacodynamic principles developed across this entire module series.
Butterworth JF, Mackey DC, Wasnick JD, eds. Morgan and Mikhail’s Clinical Anesthesiology. 6th ed. New York: McGraw-Hill; 2018:937–992.
Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. Anaesthesia. 2009;64(6):643–651.
doi:10.1111/j.1365-2044.2008.05817.xApfel CC, Saxena A, Cakmakkaya OS, Gaiser R, George E, Radke O. Prevention of postdural puncture headache after accidental dural puncture: a quantitative systematic review. Br J Anaesth. 2010;105(3):255–263.
doi:10.1093/bja/aeq191Carvalho B, Durbin M, Drover DR, Cohen SE, Ginosar Y, Riley ET. The incidence of motor block with 0.125% versus 0.0625% bupivacaine with fentanyl for labor epidural analgesia. Anesth Analg. 2003;96(5):1468–1472.
doi:10.1213/01.ANE.0000060650.10492.A4Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. Reg Anesth Pain Med. 2018;43(3):263–309.
doi:10.1097/AAP.0000000000000763Ilfeld BM. Continuous peripheral nerve blocks: a review of the published evidence. Anesth Analg. 2011;113(4):904–925.
doi:10.1213/ANE.0b013e3182285e01Guay J, Nishimori M, Kopp S. Epidural local anaesthetics versus opioid-based analgesic regimens for postoperative gastrointestinal paralysis, vomiting and pain after abdominal surgery. Cochrane Database Syst Rev. 2016;7:CD001893.
doi:10.1002/14651858.CD001893.pub2Hadzic A, ed. Hadzic’s Peripheral Nerve Blocks and Anatomy for Ultrasound-Guided Regional Anesthesia. 2nd ed. New York: McGraw-Hill; 2011.
Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564–575.
doi:10.1016/j.rapm.2004.08.003